Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 14/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 14/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 14/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.30 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203268 | 0.91 | SCN9A (0.37) | MAPK13MAPK12MAPK11MAPK14SCN9A | |
| SCHEMBL6204622 | 0.76 | SCN9A (0.37) | MAPK13MAPK12MAPK11MAPK14SCN9A | |
| SCHEMBL6204616 | 0.75 | SLC6A9 (0.39) | THRBALOX12KMT2AALDH1A1 | |
| SCHEMBL6202738 | 0.70 | THRB (0.33) | MAPK13MAPK12MAPK11MAPK14THRB | |
| SCHEMBL6204650 | 0.69 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6199767 | 0.69 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6199679 | 0.68 | MAPK14 (0.48) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6202147 | 0.67 | MAPK14 (0.51) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6203113 | 0.66 | MAPK14 (0.73) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6203111 | 0.66 | MAPK14 (0.73) | MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427727-B1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | PROCTER & GAMBLE (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6821971-B2 | FOR PROPHYALXIS OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE (IBS), SEPTIC SHOCK, CARDIOPULMONARY DYSFUNCTION, ACUTE RESPIRATORY DISEASE, CACHEXIA | THE PROCTER & GAMBLE COMPANY | 2004-11-23 | — | — | US | disclosed |
| EP-1427727-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003024970-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | IL1B, IL1A, TNF | MAPK13 2109/4885MAPK12 2598/4885MAPK11 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.